SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)		3 Months Ended								12 Months Ended
	Jul. 02, 2015 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2016 USD ($) segment reporting_unit	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Allowance for doubtful accounts		$ 300,000				$ 0				$ 300,000	$ 0
Bad debt expense										200,000	100,000	$ 0
PV of short term receivable		46,849,000				46,849,000				46,849,000	46,849,000
PV of long term receivable		0				45,573,000				0	45,573,000
Inventory reserve		600,000				300,000				$ 600,000	300,000
Number of segments | segment										1
Number of reporting units | reporting_unit										1
Goodwill, impairment										$ 0	0	0
Impairment of intangible assets										0	4,700,000	0
Income tax benefit (provision)		3,684,000	$ (6,467,000)	$ 7,392,000	$ 5,070,000	10,525,000	$ (38,761,000)	$ (15,000)	$ 40,021,000	9,679,000	11,770,000	$ 2,460,000
Prepaid tax asset related to intra-entity transfer		4,900,000								4,900,000
Investments that would be affected by ASU 2016-16		$ 214,871,000				$ 191,799,000				214,871,000	191,799,000
Asset Purchase Agreement | Asklepion Pharmaceuticals LLC
Summary Of Significant Accounting Policies [Line Items]
Proceeds from sale of assets	$ 245,000,000
Discount rate of receivables	2.80%
At Time Of Closing | Asset Purchase Agreement
Summary Of Significant Accounting Policies [Line Items]
PV of short term and long term receivables	$ 46,200,000
At Time Of Closing | Asset Purchase Agreement | Asklepion Pharmaceuticals LLC
Summary Of Significant Accounting Policies [Line Items]
Proceeds from sale of assets	150,000,000
Due On First And Second Anniversaries Of Closing | Asset Purchase Agreement
Summary Of Significant Accounting Policies [Line Items]
Proceeds from sale of assets	47,500,000
PV of short term and long term receivables	44,900,000
Due On First And Second Anniversaries Of Closing | Asset Purchase Agreement | Asklepion Pharmaceuticals LLC
Summary Of Significant Accounting Policies [Line Items]
Proceeds from sale of assets	$ 47,500,000
Interest expense, net | Asset Purchase Agreement | Asklepion Pharmaceuticals LLC
Summary Of Significant Accounting Policies [Line Items]
Accretion on the notes receivable										1,900,000
Pro Forma | Accounting Standards Update 2016-09
Summary Of Significant Accounting Policies [Line Items]
Income tax benefit (provision)										$ (400,000)	$ 2,400,000